Tomasiuk Joanna Magdalena, Nowakowska-Płaza Anna, Wisłowska Małgorzata, Głuszko Piotr
Department of Rheumatology, National Institute of Geriatric, Rheumatology and Rehabilitation, Warsaw, Poland.
Reumatologia. 2023;61(4):294-304. doi: 10.5114/reum/170048. Epub 2023 Sep 3.
In this review, the authors aimed to clarify the relationship between the occurrence of osteoporosis and diabetes, analyze the differences between the pathogenesis of osteoporosis in different types of diabetes and propose the most effective diagnostic strategy and fracture risk assessment in diabetic patients.
A analysis of publications in MEDLINE, COCHRANE and SCOPUS databases was performed, searching for reports on the diagnostics, fracture risk assessment, prevention, and treatment of osteoporosis in patients with diabetes mellitus (DM) published in the years 2016-2022. The key words for the search were: diabetes, osteoporosis, and low-energy fracture.
Bone complications of T1DM are more severe than T2DM, because of the lack of anabolic effect of insulin on bones. In T2DM the risk of fractures is elevated; however, identifying the mechanisms underlying the increased risk of fractures in T2DM is not clear. The FRAX tool is not appropriate for assessing the fracture risk in young patients with T1DM. It is quite useful in older patients with T2DM, but in these patients the calculated fracture risk may be underestimated. In T2DM the fracture risk often does not correspond to BMD value as measured by dual-energy X-ray absorptiometry (DXA). Diagnostic tools such as the trabecular bone score may play a significant role in this group of patients. Conclusions: Optimal strategies to identify and treat high risk individuals require further research and proper definition. The diagnostic criteria for osteoporosis should be clearly defined as well as fracture risk assessment and choice of anti-osteoporotic medication. In all cases of secondary osteoporosis, treatment of the underlying disease is the most important. The relationship between high risk of fractures and diabetes is inseparable, and its full understanding seems to be the key to effective management.
在本综述中,作者旨在阐明骨质疏松症与糖尿病发生之间的关系,分析不同类型糖尿病中骨质疏松症发病机制的差异,并提出糖尿病患者最有效的诊断策略和骨折风险评估方法。
对MEDLINE、COCHRANE和SCOPUS数据库中的出版物进行分析,检索2016 - 2022年发表的关于糖尿病患者骨质疏松症的诊断、骨折风险评估、预防和治疗的报告。检索关键词为:糖尿病、骨质疏松症和低能量骨折。
由于胰岛素对骨骼缺乏合成代谢作用,1型糖尿病的骨并发症比2型糖尿病更严重。在2型糖尿病中,骨折风险升高;然而,确定2型糖尿病骨折风险增加的潜在机制尚不清楚。FRAX工具不适用于评估年轻1型糖尿病患者的骨折风险。它在老年2型糖尿病患者中相当有用,但在这些患者中,计算出的骨折风险可能被低估。在2型糖尿病中,骨折风险往往与双能X线吸收法(DXA)测量的骨密度值不相符。小梁骨评分等诊断工具可能在这类患者中发挥重要作用。结论:识别和治疗高危个体的最佳策略需要进一步研究和明确界定。应明确骨质疏松症的诊断标准以及骨折风险评估和抗骨质疏松药物的选择。在所有继发性骨质疏松症病例中,治疗基础疾病是最重要的。骨折高风险与糖尿病之间的关系密不可分,充分理解这一点似乎是有效管理的关键